GSK appeals to parents with latest meningitis B ad by Beth Snyder Bulik Monday, August 12, 2019 Back to college usually means meningitis vaccine marketing, and that's exactly what GlaxoSmithKline is doing.
New MenB awareness drive backs up GSK, Pfizer by Beth Snyder Bulik Thursday, May 2, 2019 A new meningitis B awareness drive from PatientPoint and Meningitis B Action Project puts materials in waiting rooms to spur vaccinations.
GlaxoSmithKline weighs Bexsero's promise against gonorrhea by Eric Sagonowsky Tuesday, November 27, 2018 After a study showed meningitis B vaccines can protect against gonorrhea, Bexsero maker GSK is weighing whether its vaccine can fight the disease.
GSK renews Bexsero's back-to-college TV push by Beth Snyder Bulik Friday, August 31, 2018 GlaxoSmithKline's moms against meningitis B are back on the air in TV ads promoting its Bexsero vaccine for back-to-college.
4. Pfizer by Angus Liu Pfizer’s vaccines business has for years centered on Prevnar 13, the world’s bestselling vaccine, and 2017 was no exception. But the company wants to change that—and for good reason.
Hey, college-bound kids: Get your men B shot, GSK urges by Beth Snyder Bulik Wednesday, June 13, 2018 While you’re packing to leave for school, get vaccinated against meningitis B, GSK urges students in a new awareness push.
Glaxo's Shingrix should chip in $600M this year, execs say by Eric Sagonowsky Monday, April 30, 2018 GSK's Shingrix carried high expectations, but it turns out that even those ambitious projections weren't high enough.
Pfizer's Trumenba shot nabs 'breakthrough' tag for new use by Angus Liu Tuesday, April 24, 2018 The Pfizer men B shot grabs an approval-speeding designation just two months after GSK's Bexsero—Trumenba's archrival—got the same boost.
Merck's Gardasil 9 vaccine runs scarce in U.K. by Eric Sagonowsky Friday, April 13, 2018 Merck's Gardasil 9 has been on an upward trajectory, but high global demand for the HPV shot has created a shortage for U.K. private clinics.
GSK tops its peers with $7.16B in 2017 vaccine sales by Eric Sagonowsky Tuesday, February 13, 2018 While only in the very early stages of its important Shingrix launch, GlaxoSmithKline turned in enough vaccine sales to lead the industry in 2017.
